Reporting of Randomized Clinical Trials Remains Far from Optimal J. Rick Turner Editorial 30 December 2018 Pages: 137 - 139
Introduction to the Special Section for Sources of Safety Data and Statistical Strategies for Design and Analysis Richard C. Zink Special Section: Sources of Safety Data and Statistical Strategies for Design and Analysis 30 December 2018 Pages: 140 - 140
Sources of Safety Data and Statistical Strategies for Design and Analysis: Clinical Trials Richard C. ZinkOlga MarchenkoQi Jiang Special Section: Sources of Safety Data and Statistical Strategies for Design and Analysis 30 December 2018 Pages: 141 - 158
Sources of Safety Data and Statistical Strategies for Design and Analysis: Postmarket Surveillance Rima IzemMatilde Sanchez-KamYueqin Zhao Special Section: Sources of Safety Data and Statistical Strategies for Design and Analysis 30 December 2018 Pages: 159 - 169
Sources of Safety Data and Statistical Strategies for Design and Analysis: Real World Insights Olga MarchenkoEstelle Russek-CohenQi Jiang Special Section: Sources of Safety Data and Statistical Strategies for Design and Analysis 30 December 2018 Pages: 170 - 186
Sources of Safety Data and Statistical Strategies for Design and Analysis: Transforming Data Into Evidence Haijun MaEstelle Russek-CohenQi Jiang Special Section: Sources of Safety Data and Statistical Strategies for Design and Analysis 30 December 2018 Pages: 187 - 198
Extrapolation of Efficacy in Pediatric Drug Development and Evidence-based Medicine: Progress and Lessons Learned Haihao SunJean W. TemeckDianne Murphy Biostatistics: Original Research 30 December 2018 Pages: 199 - 205
The Rules of Engagement: CTTI Recommendations for Successful Collaborations Between Sponsors and Patient Groups Around Clinical Trials Diane BloomJoel BeetschJamie N. Roberts Clinical Trials: Original Research Open access 30 December 2018 Pages: 206 - 213
What to Know About Medicines With New Active Ingredients Approved in FY 2016/2016 in Japan and EU: A Brief Comparison of New Medicines Approved in Japan and the EU in 2016 Hideyuki KondoAgnès Saint-RaymondNaoyuki Yasuda Global Perspectives: Commentary 30 December 2018 Pages: 214 - 219
Assessing the Financial Value of Patient Engagement: A Quantitative Approach from CTTI’s Patient Groups and Clinical Trials Project Bennett LevitanKenneth GetzJoseph DiMasi Patient Engagement: Original Research Open access 30 December 2018 Pages: 220 - 229
Design of Brand Names of Medicines Considering Subjects’ Preferences Carla Maria Batista Ferreira PiresAfonso Cavaco Patient Engagement: Original Research 30 December 2018 Pages: 230 - 235
Patient Drug Safety Reporting: Diabetes Patients’ Perceptions of Drug Safety and How to Improve Reporting of Adverse Events and Product Complaints Puja PatelDavid SpearsMichael Sacco Product Safety: Original Research 30 December 2018 Pages: 236 - 243
Translating New Science Into the Drug Review Process: The US FDA’s Division of Applied Regulatory Science Rodney RouseNaomi KruhlakDavid G. Strauss Regulatory Science: Review Open access 30 December 2018 Pages: 244 - 255
Use of Proprietary Names by Prescribers for Generic Products Vicky Borders-HemphillIrene Z. ChanGrace Chai Regulatory Science: Original Research 30 December 2018 Pages: 256 - 260
